Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers.

31 octobre 2013 mis à jour par: Boehringer Ingelheim

Pharmacokinetics, Safety and Tolerability of BI 671800 HEA Given 200 mg b.i.d. or 400 mg b.i.d. Over 7 Days. A Randomised, Double Blind, Placebo Controlled Within Dose Groups Phase I Study in Healthy Male and Female Volunteers.

The main objectives of the multiple dose study are to investigate the safety, tolerability pharmacokinetics of BI 671800 HEA in healthy male and female volunteers following multiple oral administration of BI 671800

Aperçu de l'étude

Statut

Complété

Les conditions

Type d'étude

Interventionnel

Inscription (Réel)

24

Phase

  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

      • Ingelheim, Allemagne
        • 1268.59.1 Boehringer Ingelheim Investigational Site

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

21 ans à 50 ans (Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion criteria:

  1. Healthy males and females according to the following criteria: Based upon a complete medical history, including physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests
  2. Age 21 to 50 years (incl.)
  3. Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.)
  4. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation

Exclusion criteria:

  1. Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
  2. Any evidence of a clinically relevant concomitant disease
  3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  5. History of relevant orthostatic hypotension, fainting spells or blackouts
  6. Chronic or relevant acute infections
  7. History of relevant allergy or hypersensitivity (including allergy to drug or its excipients)
  8. Intake of drugs with a long half life (>24 h) within one month or less than 10 half-lives of the respective drug prior to first study drug administration
  9. Participation in another trial with an investigational drug within 2 months prior to administration or during the trial
  10. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes daily)
  11. Alcohol abuse (average consumption of more than 20 g/day in females and 30 g/day in males) or positive alcohol test
  12. Drug abuse
  13. Blood donation (more than 100 mL within four weeks prior to day 1 of visit 2)
  14. Any laboratory value outside the reference range that is of clinical relevance, especially repeated Alanine transaminase (ALT), Aspartate transaminase (AST), Gamma-glutamyl-transferase (GGT), Alkaline phosphatase (ALP) or total bilirubin above upper limit of normal (ULN) at screening and not resolved before dosing.
  15. Inability to comply with dietary regimen of trial site
  16. Use of drugs which might reasonably influence the results of the trial or that prolong the QT/QTc interval within 10 days prior to administration or during the trial, and CYP2C8 substrates such as amiodarone, amodiaquine, paclitaxel, rosiglitazone, pioglitazone and repaglinide or CYP2C9 such as warfarin, tolbutamide, phenytoin, losartan, acenocoumarol within 1 month or six half lives (whichever is greater).
  17. Repeated demonstration of a QTc interval >450 ms, PR interval >230 ms or a QRS interval >120 ms; history of additional risk factors for torsade de pointes (e.g., heart failure, hypokalaemia, family history of Long QT Syndrome)

    For female subjects of childbearing potential only:

  18. Positive pregnancy test, pregnancy or planning to become pregnant during the study or within 2 months after study completion
  19. No adequate contraception during the study including three months before first dosing until 2 month after study completion, e.g. not any of the following: implants, injectables, combined hormonal contraceptives, intrauterine device, or surgical sterilisation (including hysterectomy). In addition to this, also a barrier method (e.g. condom) will be required, if the female is not surgically sterilised.
  20. Lactation

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: BI 671800 HEA medium dose
Tablet, oral administration with 240 mL of water for each treatment
High dose oral administration
Medium dose oral administration
Expérimental: BI 671800 HEA high dose
2 Tablets, oral administration with 240 mL of water for each treatment
High dose oral administration
Medium dose oral administration
Comparateur placebo: Placebo
Matching to HEA 200 mg tablets, oral administration
Matching to HEA 200 mg tablet, oral administration

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Délai
Événements indésirables
Délai: 12 semaines
12 semaines
Vital signs (pulse rate (PR))
Délai: 12 weeks
12 weeks
Clinical laboratory test (clinical chemistry)
Délai: 12 weeks
12 weeks
Clinical laboratory test (urinalysis)
Délai: 12 weeks
12 weeks
Physical examination
Délai: 12 weeks
12 weeks
Vital signs (blood pressure (BP))
Délai: 12 weeks
12 weeks
12-lead ECG (electrocardiogram)
Délai: 12 weeks
12 weeks
Clinical laboratory test (haematology)
Délai: 12 weeks
12 weeks
Assessment of tolerability by investigator
Délai: 12 weeks
12 weeks

Mesures de résultats secondaires

Mesure des résultats
Délai
Cmax (maximum plasma concentration of BI 671800 or BI 600957)
Délai: up to day 12 post treatment
up to day 12 post treatment
tmax (time from dosing until maximum concentration of BI 671800 or BI 600957 is measured)
Délai: up to day 12 post treatment
up to day 12 post treatment
AUC0-infinity (area under the plasma concentration-time curve of BI 671800 or BI 600957 from time of dosing extrapolated to infinity)
Délai: up to day 12 post treatment
up to day 12 post treatment
AUCτ,1 (area under the plasma concentration-time curve of BI 671800 or BI 600957 for the complete dosing interval τ)
Délai: up to day 12 post treatment
up to day 12 post treatment
AUC0-tz (area under the plasma concentration-time curve of BI 671800 or BI 600957 from time of dosing to time tz of last quantifiable concentration)
Délai: up to day 12 post treatment
up to day 12 post treatment
Cmax,ss (maximum plasma concentration of BI 671800 or BI 600957 at steady state)
Délai: up to day 12 post treatment
up to day 12 post treatment
tmax,ss (time from dosing until maximum concentration of BI 671800 or BI 600957 at steady state is measured)
Délai: up to day 12 post treatment
up to day 12 post treatment
Cavg,ss (average measured plasma concentration of BI 671800 or BI 600957 at steady state)
Délai: up to day 12 post treatment
up to day 12 post treatment
AUCτ,ss (area under the plasma concentration-time curve of BI 671800 or BI 600957 at steady state for the complete dosing interval τ)
Délai: up to day 12 post treatment
up to day 12 post treatment
λz,ss (terminal rate constant of BI 671800 or BI 600957 in plasma at steady state)
Délai: up to day 12 post treatment
up to day 12 post treatment
t1/2,ss (terminal half-life of BI 671800 or BI 600957 in plasma at steady state)
Délai: up to day 12 post treatment
up to day 12 post treatment
MRTpo,ss (mean residence time of BI 671800 in the body at steady state after oral administration)
Délai: up to day 12 post treatment
up to day 12 post treatment
CL/F,ss (apparent clearance of BI 671800 at steady state following oral administration)
Délai: up to day 12 post treatment
up to day 12 post treatment
Vz/F,ss (apparent volume of distribution of BI 671800 during the terminal phase at steady state following oral administration)
Délai: up to day 12 post treatment
up to day 12 post treatment
RAUCτ,ss,M/P (ratio of AUCτ,ss of the BI 600957 to AUCτ,ss of BI 671800)
Délai: up to day 12 post treatment
up to day 12 post treatment
RCmax,ss,M/P (ratio of Cmax,ss of the BI 600957 to Cmax,ss of BI 671800)
Délai: up to day 12 post treatment
up to day 12 post treatment
accumulation ratios RA,Cmax
Délai: up to day 12 post treatment
up to day 12 post treatment
accumulation ratios RA,AUC
Délai: up to day 12 post treatment
up to day 12 post treatment
peak-trough fluctuation (PTF) of BI 671800
Délai: up to day 12 post treatment
up to day 12 post treatment
peak-trough fluctuation (PTF) of BI 600957
Délai: up to day 12 post treatment
up to day 12 post treatment
linearity index (LI) of BI 671800 in plasma
Délai: up to day 12 post treatment
up to day 12 post treatment

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 octobre 2010

Achèvement primaire (Réel)

1 décembre 2010

Dates d'inscription aux études

Première soumission

29 septembre 2010

Première soumission répondant aux critères de contrôle qualité

6 octobre 2010

Première publication (Estimation)

7 octobre 2010

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Estimation)

1 novembre 2013

Dernière mise à jour soumise répondant aux critères de contrôle qualité

31 octobre 2013

Dernière vérification

1 octobre 2013

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 1268.59
  • 2009-016369-27 (Numéro EudraCT: EudraCT)

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner